Katsuaki Usami
Principal Investigator, Innovation Center Kyowa Kirin
Seminars
Wednesday 10th June 2026
Novel Tetravalent Bispecific Antibody, PSMA/TRAIL‑R2 REGULGENT™, Induces Selective Tumor Cell Apoptosis Without Hepatotoxicity
3:00 pm
- Explore how a novel tetravalent PSMA/TRAIL‑R2 bispecific antibody (REGULGENT™) was engineered to enable potent TRAIL‑R2 clustering while restricting activation to PSMA‑expressing tumor cells
- Discover how the molecule selectively induced apoptosis in PSMA/TRAIL‑R2 double‑positive tumor cells, demonstrating superior activity compared with bivalent bispecific formats
- Discuss comprehensive in vitro and in vivo studies which confirmed that REGULGENT™ achieves tumor‑specific killing without hepatotoxicity, highlighting its potential as a safer TRAIL‑R2‑targeted therapy
